Skip to main
NTLA
NTLA logo

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics (NTLA) Analyst Ratings

Based on 34 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Intellia Therapeutics is positioned favorably due to significant improvements observed in patient quality of life metrics and functional capabilities following treatment with its gene editing therapies, particularly NTLA-2002. The company has successfully demonstrated substantial reductions in angioedema attacks and improved overall health outcomes, which indicate the potential for transformative therapeutic options in genetically defined diseases. Additionally, the ongoing collaborations with established industry players such as Regeneron and Novartis not only bolster Intellia's research pipeline but also enhance its commercial prospects, contributing to a positive long-term growth outlook.

Bears say

Intellia Therapeutics is facing a challenging landscape characterized by significant regulatory risks, as the potential failure to obtain approvals for its therapies could lead to downward revisions in its financial projections. The company's net present value (NPV) modeling reflects a cautious outlook, with a reduced NPV/share attributed to factors like sentiment, the engineered immune cell platform, and the in vivo therapeutics platform, highlighting concerns over future performance. Additionally, competitive threats from advanced treatment options, such as Alnylam's next-generation RNAi asset, pose further risks to Intellia's market positioning and long-term growth potential.

Intellia Therapeutics (NTLA) has been analyzed by 34 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Intellia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Intellia Therapeutics (NTLA) Forecast

Analysts have given Intellia Therapeutics (NTLA) a Buy based on their latest research and market trends.

According to 34 analysts, Intellia Therapeutics (NTLA) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Intellia Therapeutics (NTLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.